After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

Bio­gen is div­ing in­to the RNAi field with City Ther­a­peu­tics, a biotech led by sev­er­al for­mer Al­ny­lam lead­ers.

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

Devoted Health, the Medicare Advantage insurer with a medical group, has laid off about 120 employees. The layoffs, which ...

InflaRx halts Phase 3 trial of Gohibic for pyoderma gangrenosum after interim analysis shows likely failure; will focus on ...

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Hetero Labs could launch its generic sleep disorder drug as early as 2040 under a settlement deal with Axsome Therapeutics.

Angelini will pay $50 million upfront and up to $520 million in biobucks to Grin for the ex-North America rights to ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.